CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitiveEGFRinhibitor with anIC₅₀of 0.3 μM. CGP52411 blocks the toxic influx of Ca²⁺ions into neuronal cells, and dramatic inhibits and reverses the formation ofβ-amyloid (Aβ42)fibril aggregates associated with Alzheimer's disease^[1][2].

CGP52411 (DAPH; 0-100 μM; 90 minutes; A431 cells) treatment inhibits autophosphorylation and c-src autophosphorylation in vitro in a dose-dependent manner withIC₅₀s of 1 μM and 16 μM, respectively. CGP52411 treatment also shows a concentration-dependent reduction in tyrosine phosphorylation of p185c-erbB2 with anIC₅₀value of 10 μM^[1].
CGP52411 (DAPH) inhibits c-src kinase with anIC₅₀value of 16 μM. CGP52411 inhibits PKC isozymes isolated from porcine brain with anIC₅₀of 80 μM. CGP52411 inhibits conventional PKC isozymes (cPKCs α, β-1, β-2, and γ) but not nonconventional PKC isozymes (nPKCs δ, ε, and ζ) or atypical PKC isozymes (aPKC η)^[1].

CGP52411 (3.2 mg/kg, 6.3 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg; oral administration; daily; for 15 days; female BALB/c nude mice) treatment in vivo against xenografts of the A431 and SK-OV-3 tumors, and has antitumor activity^[1].

329.35

Solid

C₂₀H₁₅N₃O₂

145915-58-8

Room temperature in continental US; may vary elsewhere.

DMSO : 100 mg/mL(303.63 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。